Univariable and multivariable Cox analysis of pathway-based risk score and clinicopathological factors (TMB, age, sex and stage) for OS in the melanoma cohorts
| . | Univariable analysis . | Multivariable analysis . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P-value . | HR . | 95% CI . | P-value . | |
| Training cohort | ||||||
| Risk score (low versus high) | 0.31 | 0.19–0.49 | <0.01 | 0.21 | 0.12–0.39 | <0.01 |
| TMB (high versus low) | 0.73 | 0.43–1.22 | 0.23 | 1.31 | 0.69–2.49 | 0.42 |
| Sex (male versus female) | 0.83 | 0.51–1.34 | 0.44 | 1.04 | 0.62–1.76 | 0.87 |
| Age (≥65 versus <65) | 1.15 | 0.74–1.79 | 0.53 | 1.33 | 0.82–2.15 | 0.24 |
| M_stage (M1 versus M0) | 4.53 | 1.42–14.40 | <0.01 | 6.10 | 1.89–19.72 | <0.01 |
| Miao cohort | ||||||
| Risk score (low versus high) | 0.62 | 0.39–1.00 | 0.05 | 0.56 | 0.33–0.95 | 0.03 |
| TMB (high versus low) | 1.15 | 0.63–2.10 | 0.66 | 1.34 | 0.67–2.68 | 0.40 |
| Sex (male versus female) | 0.85 | 0.51–1.42 | 0.54 | 0.84 | 0.48–1.47 | 0.53 |
| Age (≥65 versus <65) | 1.21 | 0.76–.93 | 0.42 | 1.31 | 0.78–2.21 | 0.30 |
| Snyder cohort | ||||||
| Risk score (low versus high) | 0.29 | 0.14–0.63 | <0.01 | 0.30 | 0.12–0.73 | <0.01 |
| TMB (high versus low) | 0.55 | 0.19–1.59 | 0.27 | 0.97 | 0.30–3.17 | 0.96 |
| Sex (male versus female) | 0.76 | 0.36–1.63 | 0.48 | 1.17 | 0.49–2.75 | 0.73 |
| Age (≥65 versus <65) | 0.57 | 0.25–1.27 | 0.17 | 0.67 | 0.29–1.55 | 0.34 |
| M_stage (M1 versus M0) | 1.27 | 0.17–9.39 | 0.81 | 0.70 | 0.08–6.03 | 0.75 |
| . | Univariable analysis . | Multivariable analysis . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P-value . | HR . | 95% CI . | P-value . | |
| Training cohort | ||||||
| Risk score (low versus high) | 0.31 | 0.19–0.49 | <0.01 | 0.21 | 0.12–0.39 | <0.01 |
| TMB (high versus low) | 0.73 | 0.43–1.22 | 0.23 | 1.31 | 0.69–2.49 | 0.42 |
| Sex (male versus female) | 0.83 | 0.51–1.34 | 0.44 | 1.04 | 0.62–1.76 | 0.87 |
| Age (≥65 versus <65) | 1.15 | 0.74–1.79 | 0.53 | 1.33 | 0.82–2.15 | 0.24 |
| M_stage (M1 versus M0) | 4.53 | 1.42–14.40 | <0.01 | 6.10 | 1.89–19.72 | <0.01 |
| Miao cohort | ||||||
| Risk score (low versus high) | 0.62 | 0.39–1.00 | 0.05 | 0.56 | 0.33–0.95 | 0.03 |
| TMB (high versus low) | 1.15 | 0.63–2.10 | 0.66 | 1.34 | 0.67–2.68 | 0.40 |
| Sex (male versus female) | 0.85 | 0.51–1.42 | 0.54 | 0.84 | 0.48–1.47 | 0.53 |
| Age (≥65 versus <65) | 1.21 | 0.76–.93 | 0.42 | 1.31 | 0.78–2.21 | 0.30 |
| Snyder cohort | ||||||
| Risk score (low versus high) | 0.29 | 0.14–0.63 | <0.01 | 0.30 | 0.12–0.73 | <0.01 |
| TMB (high versus low) | 0.55 | 0.19–1.59 | 0.27 | 0.97 | 0.30–3.17 | 0.96 |
| Sex (male versus female) | 0.76 | 0.36–1.63 | 0.48 | 1.17 | 0.49–2.75 | 0.73 |
| Age (≥65 versus <65) | 0.57 | 0.25–1.27 | 0.17 | 0.67 | 0.29–1.55 | 0.34 |
| M_stage (M1 versus M0) | 1.27 | 0.17–9.39 | 0.81 | 0.70 | 0.08–6.03 | 0.75 |
Univariable and multivariable Cox analysis of pathway-based risk score and clinicopathological factors (TMB, age, sex and stage) for OS in the melanoma cohorts
| . | Univariable analysis . | Multivariable analysis . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P-value . | HR . | 95% CI . | P-value . | |
| Training cohort | ||||||
| Risk score (low versus high) | 0.31 | 0.19–0.49 | <0.01 | 0.21 | 0.12–0.39 | <0.01 |
| TMB (high versus low) | 0.73 | 0.43–1.22 | 0.23 | 1.31 | 0.69–2.49 | 0.42 |
| Sex (male versus female) | 0.83 | 0.51–1.34 | 0.44 | 1.04 | 0.62–1.76 | 0.87 |
| Age (≥65 versus <65) | 1.15 | 0.74–1.79 | 0.53 | 1.33 | 0.82–2.15 | 0.24 |
| M_stage (M1 versus M0) | 4.53 | 1.42–14.40 | <0.01 | 6.10 | 1.89–19.72 | <0.01 |
| Miao cohort | ||||||
| Risk score (low versus high) | 0.62 | 0.39–1.00 | 0.05 | 0.56 | 0.33–0.95 | 0.03 |
| TMB (high versus low) | 1.15 | 0.63–2.10 | 0.66 | 1.34 | 0.67–2.68 | 0.40 |
| Sex (male versus female) | 0.85 | 0.51–1.42 | 0.54 | 0.84 | 0.48–1.47 | 0.53 |
| Age (≥65 versus <65) | 1.21 | 0.76–.93 | 0.42 | 1.31 | 0.78–2.21 | 0.30 |
| Snyder cohort | ||||||
| Risk score (low versus high) | 0.29 | 0.14–0.63 | <0.01 | 0.30 | 0.12–0.73 | <0.01 |
| TMB (high versus low) | 0.55 | 0.19–1.59 | 0.27 | 0.97 | 0.30–3.17 | 0.96 |
| Sex (male versus female) | 0.76 | 0.36–1.63 | 0.48 | 1.17 | 0.49–2.75 | 0.73 |
| Age (≥65 versus <65) | 0.57 | 0.25–1.27 | 0.17 | 0.67 | 0.29–1.55 | 0.34 |
| M_stage (M1 versus M0) | 1.27 | 0.17–9.39 | 0.81 | 0.70 | 0.08–6.03 | 0.75 |
| . | Univariable analysis . | Multivariable analysis . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P-value . | HR . | 95% CI . | P-value . | |
| Training cohort | ||||||
| Risk score (low versus high) | 0.31 | 0.19–0.49 | <0.01 | 0.21 | 0.12–0.39 | <0.01 |
| TMB (high versus low) | 0.73 | 0.43–1.22 | 0.23 | 1.31 | 0.69–2.49 | 0.42 |
| Sex (male versus female) | 0.83 | 0.51–1.34 | 0.44 | 1.04 | 0.62–1.76 | 0.87 |
| Age (≥65 versus <65) | 1.15 | 0.74–1.79 | 0.53 | 1.33 | 0.82–2.15 | 0.24 |
| M_stage (M1 versus M0) | 4.53 | 1.42–14.40 | <0.01 | 6.10 | 1.89–19.72 | <0.01 |
| Miao cohort | ||||||
| Risk score (low versus high) | 0.62 | 0.39–1.00 | 0.05 | 0.56 | 0.33–0.95 | 0.03 |
| TMB (high versus low) | 1.15 | 0.63–2.10 | 0.66 | 1.34 | 0.67–2.68 | 0.40 |
| Sex (male versus female) | 0.85 | 0.51–1.42 | 0.54 | 0.84 | 0.48–1.47 | 0.53 |
| Age (≥65 versus <65) | 1.21 | 0.76–.93 | 0.42 | 1.31 | 0.78–2.21 | 0.30 |
| Snyder cohort | ||||||
| Risk score (low versus high) | 0.29 | 0.14–0.63 | <0.01 | 0.30 | 0.12–0.73 | <0.01 |
| TMB (high versus low) | 0.55 | 0.19–1.59 | 0.27 | 0.97 | 0.30–3.17 | 0.96 |
| Sex (male versus female) | 0.76 | 0.36–1.63 | 0.48 | 1.17 | 0.49–2.75 | 0.73 |
| Age (≥65 versus <65) | 0.57 | 0.25–1.27 | 0.17 | 0.67 | 0.29–1.55 | 0.34 |
| M_stage (M1 versus M0) | 1.27 | 0.17–9.39 | 0.81 | 0.70 | 0.08–6.03 | 0.75 |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
